Clinical trial
A Multicenter, Randomized, Single-blind, Active Comparator Controlled Phase 2 Clinical Study on the Effectiveness, Safety and Pharmacokinetics of Pegerythropoietin Injection (RD01) in Different Medication Schemes for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
NCT04231292 is registered in ClinicalTrials.gov with Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Single-blind, Active Comparator Controlled Phase 2 Clinical Study on the Effectiveness, Safety and Pharmacokinetics of Pegerythropoietin Injection (RD01) in Different Medication Schemes for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
- Lead sponsor
- Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 1, 2020
- Completion date
- December 31, 2022
- Enrollment
- 105 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
patient of anemia in chronic renal failure with hemodialysis